ATE275979T1 - Pegylation von linker verbessert die antitumor- aktivität und verringert die toxizität von immunkonjugaten - Google Patents
Pegylation von linker verbessert die antitumor- aktivität und verringert die toxizität von immunkonjugatenInfo
- Publication number
- ATE275979T1 ATE275979T1 AT01948294T AT01948294T ATE275979T1 AT E275979 T1 ATE275979 T1 AT E275979T1 AT 01948294 T AT01948294 T AT 01948294T AT 01948294 T AT01948294 T AT 01948294T AT E275979 T1 ATE275979 T1 AT E275979T1
- Authority
- AT
- Austria
- Prior art keywords
- pegylation
- antitumor activity
- reduces toxicity
- immune conjugates
- present
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polyethers (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21133100P | 2000-06-09 | 2000-06-09 | |
| US21380400P | 2000-06-22 | 2000-06-22 | |
| PCT/US2001/018503 WO2001095942A2 (en) | 2000-06-09 | 2001-06-08 | Pegylation of linkers improves antitumor activity and reduces toxicity of immunoconjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE275979T1 true ATE275979T1 (de) | 2004-10-15 |
Family
ID=26906053
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01948294T ATE275979T1 (de) | 2000-06-09 | 2001-06-08 | Pegylation von linker verbessert die antitumor- aktivität und verringert die toxizität von immunkonjugaten |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1351709B8 (de) |
| JP (1) | JP2004503512A (de) |
| AT (1) | ATE275979T1 (de) |
| AU (2) | AU6976201A (de) |
| CA (1) | CA2411967A1 (de) |
| DE (1) | DE60105647T2 (de) |
| DK (1) | DK1351709T3 (de) |
| ES (1) | ES2228903T3 (de) |
| WO (1) | WO2001095942A2 (de) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7229841B2 (en) | 2001-04-30 | 2007-06-12 | Cytimmune Sciences, Inc. | Colloidal metal compositions and methods |
| CA2529819A1 (en) * | 2003-06-30 | 2004-09-23 | Domantis Limited | Pegylated single domain antibodies |
| WO2006008096A1 (en) * | 2004-07-16 | 2006-01-26 | Micromet Ag | Expression-enhanced polypeptides |
| ES2532942T3 (es) | 2006-03-01 | 2015-04-06 | Aduro Biotech | Listeria obtenida por ingeniería genética y métodos de uso de la misma |
| US7935804B2 (en) | 2006-03-01 | 2011-05-03 | Aduro Biotech | Engineered Listeria and methods of use thereof |
| EP2604623A3 (de) * | 2007-08-08 | 2013-10-02 | Novozymes Biopharma DK A/S | Transferrinvarianten und Konjugate |
| US9624309B2 (en) | 2007-08-15 | 2017-04-18 | Bayer Intellectual Property Gmbh | Monospecific and multispecific antibodies and method of use |
| US7800951B2 (en) | 2007-08-20 | 2010-09-21 | Marvell World Trade Ltd. | Threshold voltage digitizer for array of programmable threshold transistors |
| DK2646464T3 (en) * | 2010-12-03 | 2015-08-24 | Adamed Sp Zoo | Anti Cancer Fusion Protein |
| EP2888571B1 (de) * | 2012-08-23 | 2022-12-21 | Stemcell Technologies Inc. | Verfahren und kits für schnelle und umkehrbare biomolekulare markierung |
| WO2022178751A1 (en) * | 2021-02-25 | 2022-09-01 | Shanghai Allygen Biologics Co., Ltd. | Targeting conjugates comprising effector molecules and uses thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1124961E (pt) * | 1998-10-23 | 2007-02-28 | Amgen Inc | Compostos trombopoiéticos |
-
2001
- 2001-06-08 DE DE60105647T patent/DE60105647T2/de not_active Expired - Fee Related
- 2001-06-08 AU AU6976201A patent/AU6976201A/xx active Pending
- 2001-06-08 JP JP2002510119A patent/JP2004503512A/ja active Pending
- 2001-06-08 DK DK01948294T patent/DK1351709T3/da active
- 2001-06-08 CA CA002411967A patent/CA2411967A1/en not_active Abandoned
- 2001-06-08 AT AT01948294T patent/ATE275979T1/de not_active IP Right Cessation
- 2001-06-08 AU AU2001269762A patent/AU2001269762C1/en not_active Ceased
- 2001-06-08 ES ES01948294T patent/ES2228903T3/es not_active Expired - Lifetime
- 2001-06-08 EP EP01948294A patent/EP1351709B8/de not_active Expired - Lifetime
- 2001-06-08 WO PCT/US2001/018503 patent/WO2001095942A2/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| DE60105647T2 (de) | 2005-09-22 |
| DK1351709T3 (da) | 2005-01-31 |
| AU2001269762C1 (en) | 2005-12-22 |
| WO2001095942A2 (en) | 2001-12-20 |
| CA2411967A1 (en) | 2001-12-20 |
| WO2001095942A3 (en) | 2003-07-31 |
| AU6976201A (en) | 2001-12-24 |
| EP1351709B1 (de) | 2004-09-15 |
| JP2004503512A (ja) | 2004-02-05 |
| DE60105647D1 (de) | 2004-10-21 |
| EP1351709A2 (de) | 2003-10-15 |
| ES2228903T3 (es) | 2005-04-16 |
| AU2001269762B2 (en) | 2005-06-23 |
| EP1351709B8 (de) | 2004-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL169045A (en) | Immunoconjugates | |
| ATE275979T1 (de) | Pegylation von linker verbessert die antitumor- aktivität und verringert die toxizität von immunkonjugaten | |
| EP1017397A4 (de) | Photo-empfindlichkeit-erhöhende conjugate zur targeting von pathogene | |
| WO2005112919A8 (en) | Self-immolative linkers and drug conjugates | |
| WO2003106659A3 (en) | TOXIN-APTAMER MOLECULES AND METHODS OF USE THEREOF | |
| MXPA03011094A (es) | Citotoxinas, profarmacos, ligadores, y estabilizadores utiles para ello. | |
| PL374523A1 (en) | Calicheamicin derivative-carrier conjugates | |
| DE69830326D1 (de) | Iminbildende polysaccharide, deren herstellung und verwendung als zusatzmittel und immunstimulierende mittel | |
| IN2012DN00520A (de) | ||
| IL189461A (en) | A process for making factor pairs binds @ cells and causes @ toxic @ cells | |
| WO2000064486A3 (en) | Enzymatically activated polymeric drug conjugates | |
| WO2007038658A3 (en) | Antibody-drug conjugates and methods of use | |
| BG104871A (en) | Polyol-ifn-beta conjugates | |
| CY1106886T1 (el) | Πολυμερη προϊοντα συζευξης της neublastin και μεθοδοι χρησης αυτων | |
| NZ762865A (en) | Psma-targeting amanitin conjugates | |
| WO2018124512A3 (ko) | 압타머-약물 콘쥬게이트 및 그 용도 | |
| AU2002215904A1 (en) | Compounds with a branched linker | |
| WO2002087497A3 (en) | Therapeutic agent/ligand conjugate compositions, their methods of synthesis and use | |
| WO2007064661A3 (en) | Bifunctional metal chelating conjugates | |
| PT1107793E (pt) | Conjugados de dextrano-leptina, composicoes farmaceuticas e processos relacionados | |
| WO2005041881A3 (en) | Taxoid-fatty acid conjugates and pharmaceutical compositions thereof | |
| WO2002049672A3 (en) | Conjugates of antibodies and anticancer drugs | |
| HK1067492A1 (en) | Method of making a homogenous doxorubicin-transferrin conjugate | |
| WO2022194988A3 (en) | B-lymphocyte specific amatoxin antibody conjugates | |
| MX2022015147A (es) | Conjugados de anticuerpos biespecíficos-fármacos dirigidos al receptor del factor de crecimiento epidérmico (egfr) y glicoproteína de transmembrana de tipo 1 (muc1) y usos de los mismos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1351709 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |